Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The capsular polysaccharide of Haemophilus influenzae, particularly type b (Hib), is a high-molecular-weight polymer that forms the outermost structure of encapsulated H. influenzae bacteria. This capsule is a critical virulence factor, enabling the bacterium to evade host immune responses and cause invasive diseases such as meningitis and pneumonia, especially in children. It is composed of repeating units of polyribosyl-ribitol-phosphate (PRP). Antibodies against it confer protection against Hib disease, making it a target for vaccination strategies.
Antibodies against PRP confer protection against Hib disease. Hib conjugate vaccines induce robust immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Haemophilus influenzae Capsular Polysaccharide (None).